Based on these findings, we suppose whether the VP2 peptide can serve as a VPAC1 receptor-targeted vector for the delivery of cytotoxic antitumor drugs due to its specificity for the VPAC1 receptor and its internalization by CRC cell lines. The gene discussed is VIPR1; the disease is colorectal carcinoma.